



# A new-generation vaccine for Lyme disease offering **POWERFUL PROTECTION**

## Dual-acting Nobivac™ Lyme triggers borreliacidal antibodies against *both* OspA and OspC.

New Nobivac™ Lyme is the first vaccine specifically designed to trigger borreliacidal antibodies against two *Borrelia burgdorferi* antigens, OspA and OspC.<sup>1</sup> OspA borreliacidal antibodies kill *B. burgdorferi* in the tick's midgut. Those *Borrelia* that escape the midgut are killed by OspC borreliacidal antibodies in the tick's salivary glands or in the dog. It is this dual borreliacidal action that offers a broad level of protection against infection and helps prevent the development of subclinical arthritis.

In addition, Nobivac™ Lyme was well tolerated in hundreds of dogs given the vaccine in field trials.<sup>2</sup> Science-based, dual-acting Nobivac™ Lyme—your power to protect has never been greater.

To learn more, visit [www.intervetusa.com](http://www.intervetusa.com).

Introducing

# Nobivac™ Lyme

*A powerful new weapon against Lyme disease*

#### References:

1. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. *Clin Vaccine Immunol.* 2009;16:253–259.
2. Data on file at Intervet/Schering-Plough Animal Health.

Nobivac™ is the property of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other intellectual property laws. Copyright © 2009 Intervet International B.V. All rights reserved. SPAH-VC-266-9380